TL;DR — CJC-1295 (without DAC) is a synthetic GHRH analogue; Ipamorelin is a selective ghrelin receptor (GHSR) agonist. Combined, they activate the two distinct pathways that stimulate pulsatile growth hormone release from the anterior pituitary. The pairing is one of the most widely studied growth hormone secretagogue combinations in the research literature. B.A.B.E LABS supplies this stack via HULK and in bundles ADONIS, and GLADIATOR.
What is CJC-1295 (No DAC)?
CJC-1295 is a synthetic analogue of the endogenous 44-amino-acid peptide Growth Hormone-Releasing Hormone (GHRH). Two versions exist in the literature:
- CJC-1295 with DAC (Drug Affinity Complex) — includes a maleimide group that covalently binds to serum albumin, extending half-life into the multi-day range
- CJC-1295 without DAC — the short-acting form, also known as Mod GRF 1-29 or CJC-1295 no-DAC
The "No DAC" version is the form used in Hulk. It provides pulsatile stimulation of the GHRH receptor on pituitary somatotrophs without prolonged bioavailability — closer to the endogenous pulsatile GH release pattern.
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) classified as a selective ghrelin receptor (GHSR / growth hormone secretagogue receptor) agonist. Unlike earlier GHSR agonists (e.g., GHRP-6, GHRP-2), Ipamorelin has been characterised in the research literature as notably selective for GH release — with substantially lower effects on cortisol, prolactin, and ACTH.
Why the two are studied together?
Pituitary growth hormone release is regulated by two parallel pathways:
1. GHRH pathway — GHRH binds GHRH-R on somatotrophs → cAMP-mediated GH release
2. Ghrelin pathway — ghrelin (or synthetic GHSR agonists) binds GHSR → Gq-mediated calcium-dependent GH release
The two pathways are synergistic, not redundant. Published research has reported that co-administration of a GHRH analogue and a GHSR agonist produces GH release magnitudes greater than either compound alone — consistent with the two-pathway activation hypothesis.
The Hulk blend pairs CJC-1295 (No DAC) with Ipamorelin in a single vial specifically to study this dual-pathway activation.
Where the stack appears in the catalogue:
Purity, testing, storage:
- HPLC ≥99% per batch for both constituent peptides
- COA provided per batch
- Lyophilised: –20°C, light-protected
- Reconstituted: 2–8°C
Research-use disclaimer:
Supplied strictly for in-vitro and laboratory research. Not TGA-approved. Not for human consumption.
FAQs:
Why CJC-1295 without DAC in Hulk?
To maintain the pulsatile GH release pattern. The DAC version binds albumin and sustains serum levels, which changes the pharmacology materially.
How does Ipamorelin differ from other GHRPs (GHRP-2, GHRP-6, Hexarelin)?
Ipamorelin is characterised in the research literature as having the highest selectivity for GH release among the pentapeptide GHSR agonists, with minimal effect on cortisol, prolactin, and ACTH.
What does "pulsatile" actually mean in GH pharmacology?
Endogenous GH release occurs in discrete pulses — roughly every 3-4 hours in humans, with the largest pulse during early slow-wave sleep. The "No DAC" form preserves this pulse pattern; the DAC form flattens it into sustained exposure.